{"protocolSection":{"identificationModule":{"nctId":"NCT01550289","orgStudyIdInfo":{"id":"CYD47"},"secondaryIdInfos":[{"id":"UTN: U1111-1114-7909","type":"OTHER","domain":"WHO"}],"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India","officialTitle":"Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India."},"statusModule":{"statusVerifiedDate":"2022-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-03"},"primaryCompletionDateStruct":{"date":"2013-12","type":"ACTUAL"},"completionDateStruct":{"date":"2014-02","type":"ACTUAL"},"studyFirstSubmitDate":"2012-03-07","studyFirstSubmitQcDate":"2012-03-08","studyFirstPostDateStruct":{"date":"2012-03-09","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-09-14","resultsFirstSubmitQcDate":"2016-09-14","resultsFirstPostDateStruct":{"date":"2016-11-03","type":"ESTIMATED"},"lastUpdateSubmitDate":"2022-03-15","lastUpdatePostDateStruct":{"date":"2022-04-05","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sanofi Pasteur, a Sanofi Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The aim of this study is to evaluate the immunogenicity and safety of the CYD dengue vaccine in India adult subjects.\n\nPrimary Objectives:\n\n* To describe the neutralizing antibody response to each dengue virus serotype before the first vaccination and after each vaccination with CYD dengue vaccine in all subjects.\n* To describe the safety of the CYD dengue vaccine after each dose in all subjects.\n\nSecondary Objective:\n\n* To detect symptomatic dengue cases occurring at any time in the trial.","detailedDescription":"Participants will receive 3 doses of their randomized treatment (vaccine or placebo). Flavivirus status will be determined at baseline (before the first dose) and the vaccine immunogenicity assessment will be at 28 days after each vaccination. Reactogenicity data will be collected in all subjects after each dose. Serious adverse events and adverse events of special interest will be collected throughout the study."},"conditionsModule":{"conditions":["Dengue","Dengue Fever","Dengue Hemorrhagic Fever"],"keywords":["Dengue Fever","Dengue Hemorrhagic Fever","CYD Dengue Vaccine","Dengue Virus","Flavivirus"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":189,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group 1: CYD dengue vaccine","type":"EXPERIMENTAL","description":"Subjects will receive a dose of CYD dengue vaccine at 0, 6, and 12 months, respectively.","interventionNames":["Biological: Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus"]},{"label":"Group 2: Placebo","type":"PLACEBO_COMPARATOR","description":"Subjects will receive a dose of placebo at 0, 6, and 12 months, respectively","interventionNames":["Biological: Placebo: NaCl 0.9% solution"]}],"interventions":[{"type":"BIOLOGICAL","name":"Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus","description":"0.5 mL, Subcutaneous","armGroupLabels":["Group 1: CYD dengue vaccine"],"otherNames":["CYD Dengue vaccine"]},{"type":"BIOLOGICAL","name":"Placebo: NaCl 0.9% solution","description":"0.5 ml, Subcutaneous","armGroupLabels":["Group 2: Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Antibody Titer ≥ 10 1/Dil Against Each Dengue Virus Serotype Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT).","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)"},{"measure":"Percentage of Participants With Antibody Titer ≥ 10 1/Dil Against at Least 1, 2, 3, or 4 Dengue Virus Serotypes Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT).","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)"},{"measure":"Summary of Geometric Mean Titers of Antibodies Against Each Dengue Serotype Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT).","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)"},{"measure":"Summary of Geometric Mean Titer Ratios of Antibodies Against Each Dengue Serotype Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT).","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)"},{"measure":"Percentage of Participants With Solicited Injection-site and Systemic Reactions After Any and Each Injection With Either CYD Dengue Tetravalent Vaccine or a Placebo","description":"Solicited injection-site: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Asthenia. Grade 3 Solicited Injection site reactions: Pain Significant; prevents daily activities; Erythema and Swelling \\>100 mm. Grade 3 Solicited systemic reactions: Fever ≥39.0˚C; Headache, Malaise, Myalgia, and Asthenia Significant; prevents daily activities.","timeFrame":"Day 0 up to Day 14 post each injection"}],"secondaryOutcomes":[{"measure":"Percentage of Flavivirus-Immune Participants With Antibody Titer ≥ 10 1/Dil Against Each Dengue Serotype Before and After Each Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) immune participants at baseline are defined as those participants with ≥10 (1/dil) for at least one serotype with the parental dengue virus strain or for Japanese encephalitis (JE) virus.","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)"},{"measure":"Percentage of Flavivirus-non Immune Participants With Antibody Titer < 10 1/Dil Against Each Dengue Serotype Before and After Each Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) non-immune participants at baseline are defined as those participants with \\<10 (1/dil) for all serotypes with parental dengue virus strains and for Japanese encephalitis (JE) virus.","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)"},{"measure":"Percentage of Flavivirus-Immune Participants With Antibody Titer ≥ 10 1/Dil Against at Least 1, 2, 3, or 4 Dengue Serotypes Before and After Each Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) immune participants at baseline are defined as those participants with ≥10 (1/dil) for at least one serotype with the parental dengue virus strain or for Japanese encephalitis (JE) virus.","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)"},{"measure":"Percentage of Flavivirus-non Immune Participants With Antibody Titer < 10 1/Dil Against at Least 1, 2, 3, or 4 Dengue Serotypes Before and After Each Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) non immune participants at baseline are defined as those participants with \\<10 (1/dil) for all serotypes with parental dengue virus strains and for Japanese encephalitis (JE) virus.","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)"},{"measure":"Summary of Geometric Mean Titers of Antibodies Against Each Dengue Serotype In Flavivirus-Immune Participants Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) immune participants at baseline are defined as those participants with ≥10 (1/dil) for at least one serotype with the parental dengue virus strain or for Japanese encephalitis (JE) virus.","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)"},{"measure":"Summary of Geometric Mean Titer Ratios of Antibodies Against Each Dengue Serotype In Flavivirus-Immune Participants Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) immune participants at baseline are defined as those participants with ≥10 (1/dil) for at least one serotype with the parental dengue virus strain or for Japanese encephalitis (JE) virus.","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)"},{"measure":"Summary of Geometric Mean Titers of Antibodies Against Each Dengue Serotype In Flavivirus Non-immune Participants Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) non immune participants at baseline are defined as those participants with \\<10 (1/dil) for all serotypes with parental dengue virus strains and for Japanese encephalitis (JE) virus.","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)"},{"measure":"Summary of Geometric Mean Titer Ratios of Antibodies Against Each Dengue Serotype In Flavivirus Non-immune Participants Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) immune participants at baseline are defined as those participants with ≥10 (1/dil) for at least one serotype with the parental dengue virus strain or for Japanese encephalitis (JE) virus.","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 18 to 45 years on the day of inclusion\n* Informed consent form has been signed and dated by the subject (and by an independent witness, if applicable)\n* Subject is able to attend all scheduled visits and to comply with all trial procedures\n* Subject in good health, based on medical history and physical examination\n\nExclusion Criteria:\n\n* Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination)\n* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination\n* Planned participation in another clinical trial during the present trial period\n* Planned receipt of any vaccine in the 4 weeks following any trial vaccination\n* Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n* Known seropositivity for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C reported by the subject\n* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances\n* Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion\n* Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures\n* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily\n* Identified as an Investigator or employee of the Investigator or study center, with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Sanofi Pasteur India Pvt Ltd","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Bangalore","state":"Karnataka","zip":"560054","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"city":"Ludhiana","state":"Punjab","zip":"141008","country":"India","geoPoint":{"lat":30.91204,"lon":75.85379}},{"city":"Kolkata","state":"West Bengal","zip":"700073","country":"India","geoPoint":{"lat":22.56263,"lon":88.36304}},{"city":"New Delhi","zip":"110002","country":"India","geoPoint":{"lat":28.62137,"lon":77.2148}},{"city":"Pune","zip":"411018","country":"India","geoPoint":{"lat":18.51957,"lon":73.85535}}]},"referencesModule":{"references":[{"pmid":"26291554","type":"RESULT","citation":"Dubey AP, Agarkhedkar S, Chhatwal J, Narayan A, Ganguly S, Wartel TA, Bouckenooghe A, Menezes J. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial. Hum Vaccin Immunother. 2016;12(2):512-8. doi: 10.1080/21645515.2015.1076598."}],"seeAlsoLinks":[{"label":"Related Info","url":"http://www.sanofipasteur.com"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 189 participants who met all inclusion and no exclusion criteria were randomized and vaccinated in this trial; 187 were included in the Full Analysis Set.","recruitmentDetails":"Study participants were enrolled from 27 March 2012 to 28 June 2012 at 5 clinical centers in India.","groups":[{"id":"FG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants received 3 vaccinations of the CYD Dengue Vaccine."},{"id":"FG001","title":"Placebo Group","description":"Healthy adult participants received 3 vaccinations of placebo vaccine."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"128"},{"groupId":"FG001","numSubjects":"61"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"115"},{"groupId":"FG001","numSubjects":"57"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants received 3 vaccinations of the CYD Dengue Vaccine."},{"id":"BG001","title":"Placebo Group","description":"Healthy adult participants received 3 vaccinations of placebo vaccine."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"187"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"187"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29.5","spread":"7.17"},{"groupId":"BG001","value":"29.6","spread":"6.41"},{"groupId":"BG002","value":"29.5","spread":"6.91"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"36"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"151"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"India","categories":[{"measurements":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"187"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Antibody Titer ≥ 10 1/Dil Against Each Dengue Virus Serotype Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT).","populationDescription":"Dengue neutralizing antibody titers were assessed in the Full Analysis Set with available data for each time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants received 3 vaccinations of the CYD Dengue Vaccine."},{"id":"OG001","title":"Placebo Group","description":"Healthy adult participants received 3 vaccinations of placebo vaccine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"61"}]}],"classes":[{"title":"Serotype 1; Pre-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"83.3"},{"groupId":"OG001","value":"80.3"}]}]},{"title":"Serotype 1; Post-injection 1 (N=125, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"91.2"},{"groupId":"OG001","value":"83.6"}]}]},{"title":"Serotype 1; Post-injection 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"94.9"},{"groupId":"OG001","value":"81.0"}]}]},{"title":"Serotype 1; Post-injection 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"97.4"},{"groupId":"OG001","value":"87.7"}]}]},{"title":"Serotype 2; Pre-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"83.3"},{"groupId":"OG001","value":"86.9"}]}]},{"title":"Serotype 2; Post-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"94.4"},{"groupId":"OG001","value":"88.5"}]}]},{"title":"Serotype 2; Post-injection 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"99.1"},{"groupId":"OG001","value":"84.5"}]}]},{"title":"Serotype 2; Post-injection 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"97.4"},{"groupId":"OG001","value":"91.2"}]}]},{"title":"Serotype 3; Pre-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"84.9"},{"groupId":"OG001","value":"86.9"}]}]},{"title":"Serotype 3; Post-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"98.4"},{"groupId":"OG001","value":"90.2"}]}]},{"title":"Serotype 3; Post-injection 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"98.3"},{"groupId":"OG001","value":"84.5"}]}]},{"title":"Serotype 3; Post-injection 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"99.1"},{"groupId":"OG001","value":"89.5"}]}]},{"title":"Serotype 4; Pre-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"77.0"},{"groupId":"OG001","value":"80.3"}]}]},{"title":"Serotype 4; Post-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"96.0"},{"groupId":"OG001","value":"85.2"}]}]},{"title":"Serotype 4; Post-injection 2 (N=117, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"99.1"},{"groupId":"OG001","value":"78.9"}]}]},{"title":"Serotype 4; Post-injection 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"84.2"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Antibody Titer ≥ 10 1/Dil Against at Least 1, 2, 3, or 4 Dengue Virus Serotypes Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT).","populationDescription":"Dengue neutralizing antibody titers were assessed in the Full Analysis Set with available data for each time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants received 3 vaccinations of the CYD Dengue Vaccine."},{"id":"OG001","title":"Placebo Group","description":"Healthy adult participants received 3 vaccinations of placebo vaccine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"61"}]}],"classes":[{"title":"At least 1 serotype; Pre-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"86.5"},{"groupId":"OG001","value":"88.5"}]}]},{"title":"At least 1 serotype; Post-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"99.2"},{"groupId":"OG001","value":"90.2"}]}]},{"title":"At least 1 serotype; Post-injection 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"86.2"}]}]},{"title":"At least 1 serotype; Post-injection 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"91.2"}]}]},{"title":"At least 2 serotypes; Pre-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"84.1"},{"groupId":"OG001","value":"85.2"}]}]},{"title":"At least 2 serotypes; Post-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"98.4"},{"groupId":"OG001","value":"88.5"}]}]},{"title":"At least 2 serotypes; Post-injection 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"98.3"},{"groupId":"OG001","value":"82.8"}]}]},{"title":"At least 2 serotypes; Post-injection 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"99.1"},{"groupId":"OG001","value":"89.5"}]}]},{"title":"At least 3 serotypes; Pre-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"82.5"},{"groupId":"OG001","value":"83.6"}]}]},{"title":"At least 3 serotypes; Post-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"92.1"},{"groupId":"OG001","value":"88.5"}]}]},{"title":"At least 3 serotypes; Post-injection 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"98.3"},{"groupId":"OG001","value":"81.0"}]}]},{"title":"At least 3 serotypes; Post-injection 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"97.4"},{"groupId":"OG001","value":"87.7"}]}]},{"title":"All 4 serotypes; Pre-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"75.4"},{"groupId":"OG001","value":"77.0"}]}]},{"title":"All 4 serotypes; Post-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"89.7"},{"groupId":"OG001","value":"80.3"}]}]},{"title":"All 4 serotypes; Post-injection 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"94.9"},{"groupId":"OG001","value":"77.6"}]}]},{"title":"All 4 serotypes; Post-injection 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"97.4"},{"groupId":"OG001","value":"84.2"}]}]}]},{"type":"PRIMARY","title":"Summary of Geometric Mean Titers of Antibodies Against Each Dengue Serotype Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT).","populationDescription":"Geometric mean titers were assessed in the Full Analysis Set with available data for each time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers (1/dilutions)","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants received 3 vaccinations of the CYD Dengue Vaccine."},{"id":"OG001","title":"Placebo Group","description":"Healthy adult participants received 3 vaccinations of placebo vaccine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"61"}]}],"classes":[{"title":"Serotype 1; Pre-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"184","lowerLimit":"127","upperLimit":"268"},{"groupId":"OG001","value":"234","lowerLimit":"133","upperLimit":"409"}]}]},{"title":"Serotype 1; Post-injection 1 (N=125, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"605","lowerLimit":"410","upperLimit":"892"},{"groupId":"OG001","value":"288","lowerLimit":"161","upperLimit":"513"}]}]},{"title":"Serotype 1; Post-injection 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"556","lowerLimit":"391","upperLimit":"790"},{"groupId":"OG001","value":"294","lowerLimit":"159","upperLimit":"543"}]}]},{"title":"Serotype 1; Post-injection 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"461","lowerLimit":"340","upperLimit":"625"},{"groupId":"OG001","value":"268","lowerLimit":"164","upperLimit":"438"}]}]},{"title":"Serotype 2; Pre-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"204","lowerLimit":"141","upperLimit":"294"},{"groupId":"OG001","value":"243","lowerLimit":"147","upperLimit":"403"}]}]},{"title":"Serotype 2; Post-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"720","lowerLimit":"510","upperLimit":"1015"},{"groupId":"OG001","value":"300","lowerLimit":"184","upperLimit":"489"}]}]},{"title":"Serotype 2; Post-injection 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"787","lowerLimit":"592","upperLimit":"1045"},{"groupId":"OG001","value":"288","lowerLimit":"163","upperLimit":"509"}]}]},{"title":"Serotype 2; Post-injection 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"484","lowerLimit":"370","upperLimit":"634"},{"groupId":"OG001","value":"258","lowerLimit":"163","upperLimit":"410"}]}]},{"title":"Serotype 3; Pre-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"219","lowerLimit":"153","upperLimit":"312"},{"groupId":"OG001","value":"216","lowerLimit":"131","upperLimit":"354"}]}]},{"title":"Serotype 3; Post-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"951","lowerLimit":"691","upperLimit":"1309"},{"groupId":"OG001","value":"293","lowerLimit":"180","upperLimit":"478"}]}]},{"title":"Serotype 3; Post-injection 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"846","lowerLimit":"635","upperLimit":"1127"},{"groupId":"OG001","value":"249","lowerLimit":"143","upperLimit":"434"}]}]},{"title":"Serotype 3; Post-injection 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"709","lowerLimit":"552","upperLimit":"911"},{"groupId":"OG001","value":"268","lowerLimit":"168","upperLimit":"426"}]}]},{"title":"Serotype 4; Pre injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"55.4","lowerLimit":"41.4","upperLimit":"74.2"},{"groupId":"OG001","value":"62.0","lowerLimit":"42.0","upperLimit":"91.5"}]}]},{"title":"Serotype 4; Post-injection 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"358","lowerLimit":"271","upperLimit":"472"},{"groupId":"OG001","value":"78.7","lowerLimit":"52.7","upperLimit":"117"}]}]},{"title":"Serotype 4; Post-injection 2 (N=117, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"289","lowerLimit":"236","upperLimit":"354"},{"groupId":"OG001","value":"72.8","lowerLimit":"46.6","upperLimit":"114"}]}]},{"title":"Serotype 4; Post-injection 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"336","lowerLimit":"271","upperLimit":"417"},{"groupId":"OG001","value":"91.9","lowerLimit":"60.8","upperLimit":"139"}]}]}]},{"type":"PRIMARY","title":"Summary of Geometric Mean Titer Ratios of Antibodies Against Each Dengue Serotype Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT).","populationDescription":"Geometric mean titer ratios were assessed in the Full Analysis Set with available data for each time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer ratio","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants received 3 vaccinations of the CYD Dengue Vaccine."},{"id":"OG001","title":"Placebo Group","description":"Healthy adult participants received 3 vaccinations of placebo vaccine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"61"}]}],"classes":[{"title":"Serotype 1; Post-inj. 1/Pre-inj. 1 (N=125,61)","categories":[{"measurements":[{"groupId":"OG000","value":"3.23","lowerLimit":"2.49","upperLimit":"4.18"},{"groupId":"OG001","value":"1.23","lowerLimit":"1.02","upperLimit":"1.49"}]}]},{"title":"Serotype 1; Post-inj. 2/Pre-inj. 1 (N=117,58)","categories":[{"measurements":[{"groupId":"OG000","value":"3.15","lowerLimit":"2.46","upperLimit":"4.04"},{"groupId":"OG001","value":"1.26","lowerLimit":"1.01","upperLimit":"1.58"}]}]},{"title":"Serotype 1; Post-inj. 3/Pre-inj. 1 (N=115,57)","categories":[{"measurements":[{"groupId":"OG000","value":"2.64","lowerLimit":"2.08","upperLimit":"3.35"},{"groupId":"OG001","value":"1.18","lowerLimit":"0.838","upperLimit":"1.66"}]}]},{"title":"Serotype 2; Post-inj. 1/Pre-inj. 1 (N=126,61)","categories":[{"measurements":[{"groupId":"OG000","value":"3.53","lowerLimit":"2.76","upperLimit":"4.52"},{"groupId":"OG001","value":"1.23","lowerLimit":"1.03","upperLimit":"1.47"}]}]},{"title":"Serotype 2; Post-inj. 2/Pre-inj. 1 (N=117,58)","categories":[{"measurements":[{"groupId":"OG000","value":"3.83","lowerLimit":"2.84","upperLimit":"5.18"},{"groupId":"OG001","value":"1.17","lowerLimit":"0.951","upperLimit":"1.45"}]}]},{"title":"Serotype 2; Post-inj. 3/Pre-inj. 1 (N=115,57)","categories":[{"measurements":[{"groupId":"OG000","value":"2.38","lowerLimit":"1.81","upperLimit":"3.11"},{"groupId":"OG001","value":"1.05","lowerLimit":"0.791","upperLimit":"1.41"}]}]},{"title":"Serotype 3; Post-inj. 1/Pre-inj. 1 (N=126,61)","categories":[{"measurements":[{"groupId":"OG000","value":"4.35","lowerLimit":"3.34","upperLimit":"5.68"},{"groupId":"OG001","value":"1.36","lowerLimit":"1.09","upperLimit":"1.69"}]}]},{"title":"Serotype 3; Post-inj. 2/Pre-inj. 1 (N=117,58)","categories":[{"measurements":[{"groupId":"OG000","value":"3.97","lowerLimit":"2.99","upperLimit":"5.28"},{"groupId":"OG001","value":"1.13","lowerLimit":"0.888","upperLimit":"1.44"}]}]},{"title":"Serotype 3; Post-inj. 3/Pre-inj. 1 (N=115,57)","categories":[{"measurements":[{"groupId":"OG000","value":"3.39","lowerLimit":"2.61","upperLimit":"4.40"},{"groupId":"OG001","value":"1.22","lowerLimit":"0.869","upperLimit":"1.72"}]}]},{"title":"Serotype 4; Post-inj. 1/Pre-inj. 1 (N=126,61)","categories":[{"measurements":[{"groupId":"OG000","value":"6.46","lowerLimit":"4.74","upperLimit":"8.79"},{"groupId":"OG001","value":"1.27","lowerLimit":"1.00","upperLimit":"1.61"}]}]},{"title":"Serotype 4; Post-inj. 2/Pre-inj. 1 (N=117,57)","categories":[{"measurements":[{"groupId":"OG000","value":"5.16","lowerLimit":"3.98","upperLimit":"6.68"},{"groupId":"OG001","value":"1.15","lowerLimit":"0.920","upperLimit":"1.45"}]}]},{"title":"Serotype 4; Post-inj. 3/Pre-inj. 1 (N=115,57)","categories":[{"measurements":[{"groupId":"OG000","value":"6.11","lowerLimit":"4.81","upperLimit":"7.77"},{"groupId":"OG001","value":"1.44","lowerLimit":"1.09","upperLimit":"1.90"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Solicited Injection-site and Systemic Reactions After Any and Each Injection With Either CYD Dengue Tetravalent Vaccine or a Placebo","description":"Solicited injection-site: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Asthenia. Grade 3 Solicited Injection site reactions: Pain Significant; prevents daily activities; Erythema and Swelling \\>100 mm. Grade 3 Solicited systemic reactions: Fever ≥39.0˚C; Headache, Malaise, Myalgia, and Asthenia Significant; prevents daily activities.","populationDescription":"Solicited injection-site and systemic reactions were assessed in the Safety Analysis Set with available data for each time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Day 0 up to Day 14 post each injection","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants received 3 vaccinations of the CYD Dengue Vaccine."},{"id":"OG001","title":"Placebo Group","description":"Healthy adult participants received 3 vaccinations of placebo vaccine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"61"}]}],"classes":[{"title":"Injection-site Pain; Post-Any inj. (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"9.5"},{"groupId":"OG001","value":"4.9"}]}]},{"title":"Grade 3 Inj.-site Pain; Post-Any inj. (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Injection-site Erythema; Post-Any inj. (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Inj.-site Erythema;Post-Any inj (N=126,61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Injection-site Swelling; Post-Any inj. (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Inj.-site Swelling;PostAny inj (N=126,61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Injection-site Pain; Post-inj. 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"6.3"},{"groupId":"OG001","value":"4.9"}]}]},{"title":"Grade 3 Inj.-site Pain; Post-inj. 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Injection-site Erythema; Post-inj. 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Inj.-site Erythema; Post-inj 1 (N=126,61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Injection-site Swelling; Post-inj. 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Inj.-site Swelling; Post-inj. 1 (N=126,61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Injection-site Pain; Post-inj. 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"1.7"},{"groupId":"OG001","value":"3.4"}]}]},{"title":"Grade 3 Inj.-site Pain; Post-inj. 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Injection-site Erythema; Post-inj. 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Inj.-site Erythema; Post-inj 2 (N=117,58)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Injection-site Swelling; Post-inj. 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Inj.-site Swelling; Post-inj. 2 (N=117,58)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Injection-site Pain; Post-inj. 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"2.6"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Inj.-site Pain; Post-inj. 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Injection-site Erythema; Post-inj. 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Inj.-site Erythema; Post-inj 3 (N=115,57)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Injection-site Swelling; Post-inj. 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Inj.-site Swelling; Post-inj. 3 (N=115,57)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever; Post-Any inj. (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"1.6"}]}]},{"title":"Grade 3 Fever; Post-Any inj. (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.8"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Headache; Post Any\\-inj. (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"7.9"},{"groupId":"OG001","value":"4.9"}]}]},{"title":"Grade 3 Headache; Post-Any inj. (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"1.6"},{"groupId":"OG001","value":"1.6"}]}]},{"title":"Malaise; Post-Any inj. (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"8.7"},{"groupId":"OG001","value":"4.9"}]}]},{"title":"Grade 3 Malaise; Post-Any inj. (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.8"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Myalgia; Post Any inj. (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"9.5"},{"groupId":"OG001","value":"4.9"}]}]},{"title":"Grade 3 Myalgia; Post-Any inj. (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"1.6"}]}]},{"title":"Asthenia; Post-Any inj. (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"4.9"}]}]},{"title":"Grade 3 Asthenia; Post-Any inj. (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.8"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever; Post-inj. 1 (N=125, 60)","categories":[{"measurements":[{"groupId":"OG000","value":"4.8"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Fever; Post-inj. 1 (N=125, 60)","categories":[{"measurements":[{"groupId":"OG000","value":"0.8"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Headache; Post-inj. 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"4.9"}]}]},{"title":"Grade 3 Headache; Post-inj. 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"1.6"},{"groupId":"OG001","value":"1.6"}]}]},{"title":"Malaise; Post-inj. 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"7.1"},{"groupId":"OG001","value":"4.9"}]}]},{"title":"Grade 3 Malaise; Post-inj. 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Myalgia; Post-inj. 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"7.9"},{"groupId":"OG001","value":"4.9"}]}]},{"title":"Grade 3 Myalgia; Post inj. 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1.6"}]}]},{"title":"Asthenia; Post-inj. 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"9.5"},{"groupId":"OG001","value":"4.9"}]}]},{"title":"Grade 3 Asthenia; Post inj. 1 (N=126, 61)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever; Post-inj. 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"1.7"}]}]},{"title":"Grade 3 Fever; Post-inj. 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Headache; Post-inj. 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"1.7"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Headache; Post-inj. 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Malaise; Post-inj. 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Malaise; Post-inj. 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Myalgia; Post-inj. 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"1.7"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Myalgia; Post-inj. 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Asthenia; Post-inj. 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"2.6"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Asthenia; Post-inj. 2 (N=117, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever; Post-inj. 3 (N=113, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Fever; Post inj. 3 (N=113, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Headache; Post-inj. 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Headache; Post-inj. 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Malaise; Post-inj. 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"0.9"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Malaise; Post-inj. 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Myalgia; Post-inj. 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Myalgia; Post-inj. 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Asthenia; Post-inj. 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Grade 3 Asthenia; Post-inj. 3 (N=115, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Flavivirus-Immune Participants With Antibody Titer ≥ 10 1/Dil Against Each Dengue Serotype Before and After Each Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) immune participants at baseline are defined as those participants with ≥10 (1/dil) for at least one serotype with the parental dengue virus strain or for Japanese encephalitis (JE) virus.","populationDescription":"Dengue neutralizing antibody titers were assessed in the Full Analysis Set with available data for each time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants received 3 vaccinations of the CYD Dengue Vaccine."},{"id":"OG001","title":"Placebo Group","description":"Healthy adult participants received 3 vaccinations of placebo vaccine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"56"}]}],"classes":[{"title":"Serotype 1; Pre-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"92.9"},{"groupId":"OG001","value":"87.5"}]}]},{"title":"Serotype 1; Post-injection 1 (N=112, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"96.4"},{"groupId":"OG001","value":"89.3"}]}]},{"title":"Serotype 1; Post-injection 2 (N=104, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"99.0"},{"groupId":"OG001","value":"88.7"}]}]},{"title":"Serotype 1; Post-injection 3 (N=102, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"94.2"}]}]},{"title":"Serotype 2; Pre-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"92.9"},{"groupId":"OG001","value":"94.6"}]}]},{"title":"Serotype 2; Post-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"98.2"},{"groupId":"OG001","value":"94.6"}]}]},{"title":"Serotype 2; Post-injection 2 (N=104, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"92.5"}]}]},{"title":"Serotype 2; Post-injection 3 (N=102, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"98.1"}]}]},{"title":"Serotype 3; Pre-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"94.7"},{"groupId":"OG001","value":"94.6"}]}]},{"title":"Serotype 3; Post-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"96.4"}]}]},{"title":"Serotype 3; Post-injection 2 (N=104, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"92.5"}]}]},{"title":"Serotype 3; Post-injection 3 (N=102, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"96.2"}]}]},{"title":"Serotype 4; Pre-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"85.8"},{"groupId":"OG001","value":"87.5"}]}]},{"title":"Serotype 4; Post-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"98.2"},{"groupId":"OG001","value":"91.1"}]}]},{"title":"Serotype 4; Post-injection 2 (N=104, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"86.5"}]}]},{"title":"Serotype 4; Post-injection 3 (N=102, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"90.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Flavivirus-non Immune Participants With Antibody Titer < 10 1/Dil Against Each Dengue Serotype Before and After Each Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) non-immune participants at baseline are defined as those participants with \\<10 (1/dil) for all serotypes with parental dengue virus strains and for Japanese encephalitis (JE) virus.","populationDescription":"Dengue neutralizing antibody titers were assessed in the Full Analysis Set with available data for each time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants received 3 vaccinations of the CYD Dengue Vaccine."},{"id":"OG001","title":"Placebo Group","description":"Healthy adult participants received 3 vaccinations of placebo vaccine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}]}],"classes":[{"title":"Serotype 1; Pre-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Serotype 1; Post-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"46.2"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"Serotype 1; Post-injection 2 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"61.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Serotype 1; Post-injection 3 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"76.9"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"Serotype 2; Pre-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Serotype 2; Post-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"61.5"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"Serotype 2; Post-injection 2 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"92.3"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Serotype 2; Post injection 3 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"76.9"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"Serotype 3; Pre-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Serotype 3; Post-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"84.6"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"Serotype 3; Post-injection 2 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"84.6"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Serotype 3; Post-injection 3 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"92.3"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"Serotype 4; Pre-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Serotype 4; Post-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"76.9"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"Serotype 4; Post-injection 2 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"92.3"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Serotype 4; Post-injection 3 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"20.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Flavivirus-Immune Participants With Antibody Titer ≥ 10 1/Dil Against at Least 1, 2, 3, or 4 Dengue Serotypes Before and After Each Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) immune participants at baseline are defined as those participants with ≥10 (1/dil) for at least one serotype with the parental dengue virus strain or for Japanese encephalitis (JE) virus.","populationDescription":"Dengue neutralizing antibody titers were assessed in the Full Analysis Set with available data for each time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants received 3 vaccinations of the CYD Dengue Vaccine."},{"id":"OG001","title":"Placebo Group","description":"Healthy adult participants received 3 vaccinations of placebo vaccine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"56"}]}],"classes":[{"title":"At least 1 serotype; Pre-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"96.5"},{"groupId":"OG001","value":"96.4"}]}]},{"title":"At least 1 serotype; Post-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"96.4"}]}]},{"title":"At least 1 serotype; Post-injection 2 (N=104, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"94.3"}]}]},{"title":"At least 1 serotype; Post-injection 3 (N=102, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"98.1"}]}]},{"title":"At least 2 serotypes; Pre-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"93.8"},{"groupId":"OG001","value":"92.9"}]}]},{"title":"At least 2 serotypes; Post-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"94.6"}]}]},{"title":"At least 2 serotypes; Post-injection 2 (N=104, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"90.6"}]}]},{"title":"At least 2 serotypes; Post-injection 3 (N=102, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"96.2"}]}]},{"title":"At least 3 serotypes; Pre-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"92.0"},{"groupId":"OG001","value":"91.1"}]}]},{"title":"At least 3 serotypes; Post-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"96.5"},{"groupId":"OG001","value":"94.6"}]}]},{"title":"At least 3 serotypes; Post-injection 2 (N=104, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"88.7"}]}]},{"title":"At least 3 serotypes; Post-injection 3 (N=102, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"94.2"}]}]},{"title":"All 4 serotypes; Pre-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"84.1"},{"groupId":"OG001","value":"83.9"}]}]},{"title":"All 4 serotypes; Post-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"95.6"},{"groupId":"OG001","value":"85.7"}]}]},{"title":"All 4 serotypes; Post-injection 2 (N=104, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"99.0"},{"groupId":"OG001","value":"84.9"}]}]},{"title":"All 4 serotypes; Post-injection 3 (N=102, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"90.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Flavivirus-non Immune Participants With Antibody Titer < 10 1/Dil Against at Least 1, 2, 3, or 4 Dengue Serotypes Before and After Each Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) non immune participants at baseline are defined as those participants with \\<10 (1/dil) for all serotypes with parental dengue virus strains and for Japanese encephalitis (JE) virus.","populationDescription":"Dengue neutralizing antibody titers were assessed in the Full Analysis Set with available data for each time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants received 3 vaccinations of the CYD Dengue Vaccine."},{"id":"OG001","title":"Placebo Group","description":"Healthy adult participants received 3 vaccinations of placebo vaccine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}]}],"classes":[{"title":"At least 1 serotype; Pre-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"At least 1 serotype; Post-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"92.3"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"At least 1 serotype; Post-injection 2 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"At least 1 serotype; Post-injection 3 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"At least 2 serotypes; Pre-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"At least 2 serotypes; Post-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"84.6"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"At least 2 serotypes; Post-injection 2 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"84.6"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"At least 2 serotypes; Post-injection 3 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"92.3"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"At least 3 serotypes; Pre-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"At least 3 serotypes; Post-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"53.8"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"At least 3 serotypes; Post-injection 2 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"84.6"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"At least 3 serotypes; Post-injection 3 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"76.9"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"All 4 serotypes; Pre-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"All 4 serotypes; Post-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"38.5"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"All 4 serotypes; Post-injection 2 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"61.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"All 4 serotypes; Post-injection 3 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"76.9"},{"groupId":"OG001","value":"20.0"}]}]}]},{"type":"SECONDARY","title":"Summary of Geometric Mean Titers of Antibodies Against Each Dengue Serotype In Flavivirus-Immune Participants Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) immune participants at baseline are defined as those participants with ≥10 (1/dil) for at least one serotype with the parental dengue virus strain or for Japanese encephalitis (JE) virus.","populationDescription":"Geometric mean titers were assessed in the Full Analysis Set with available data for each time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers (1/dilutions)","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants who received 3 vaccinations of the CYD Dengue Vaccine."},{"id":"OG001","title":"Placebo Group","description":"Healthy adult participants who received 3 vaccinations of placebo vaccine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"56"}]}],"classes":[{"title":"Serotype 1; Pre-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"279","lowerLimit":"199","upperLimit":"392"},{"groupId":"OG001","value":"329","lowerLimit":"196","upperLimit":"553"}]}]},{"title":"Serotype 1; Post-injection 1 (N=112, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"925","lowerLimit":"656","upperLimit":"1304"},{"groupId":"OG001","value":"401","lowerLimit":"232","upperLimit":"691"}]}]},{"title":"Serotype 1; Post-injection 2 (N=104, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"807","lowerLimit":"591","upperLimit":"1101"},{"groupId":"OG001","value":"432","lowerLimit":"245","upperLimit":"760"}]}]},{"title":"Serotype 1; Post-injection 3 (N=102, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"636","lowerLimit":"485","upperLimit":"834"},{"groupId":"OG001","value":"362","lowerLimit":"235","upperLimit":"558"}]}]},{"title":"Serotype 2; Pre-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"312","lowerLimit":"225","upperLimit":"432"},{"groupId":"OG001","value":"344","lowerLimit":"221","upperLimit":"537"}]}]},{"title":"Serotype 2; Post-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"1030","lowerLimit":"765","upperLimit":"1385"},{"groupId":"OG001","value":"413","lowerLimit":"268","upperLimit":"636"}]}]},{"title":"Serotype 2; Post-injection 2 (N=104, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"1010","lowerLimit":"792","upperLimit":"1288"},{"groupId":"OG001","value":"422","lowerLimit":"254","upperLimit":"702"}]}]},{"title":"Serotype 2; Post-injection 3 (N=102, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"624","lowerLimit":"493","upperLimit":"790"},{"groupId":"OG001","value":"357","lowerLimit":"242","upperLimit":"528"}]}]},{"title":"Serotype 3; Pre-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"338","lowerLimit":"249","upperLimit":"458"},{"groupId":"OG001","value":"302","lowerLimit":"195","upperLimit":"469"}]}]},{"title":"Serotype 3; Post-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"1324","lowerLimit":"1002","upperLimit":"1749"},{"groupId":"OG001","value":"405","lowerLimit":"263","upperLimit":"623"}]}]},{"title":"Serotype 3; Post-injection 2 (N=104, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"1131","lowerLimit":"879","upperLimit":"1455"},{"groupId":"OG001","value":"361","lowerLimit":"219","upperLimit":"594"}]}]},{"title":"Serotype 3; Post-injection 3 (N=102, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"912","lowerLimit":"726","upperLimit":"1145"},{"groupId":"OG001","value":"368","lowerLimit":"248","upperLimit":"547"}]}]},{"title":"Serotype 4; Pre-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"73.1","lowerLimit":"55.1","upperLimit":"96.9"},{"groupId":"OG001","value":"77.6","lowerLimit":"53.6","upperLimit":"112"}]}]},{"title":"Serotype 4; Post-injection 1 (N=113, 56)","categories":[{"measurements":[{"groupId":"OG000","value":"424","lowerLimit":"325","upperLimit":"554"},{"groupId":"OG001","value":"99.1","lowerLimit":"67.8","upperLimit":"145"}]}]},{"title":"Serotype 4; Post-injection 2 (N=104, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"346","lowerLimit":"287","upperLimit":"417"},{"groupId":"OG001","value":"94.2","lowerLimit":"61.6","upperLimit":"144"}]}]},{"title":"Serotype 4; Post-injection 3 (N=102, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"387","lowerLimit":"309","upperLimit":"485"},{"groupId":"OG001","value":"117","lowerLimit":"79.7","upperLimit":"172"}]}]}]},{"type":"SECONDARY","title":"Summary of Geometric Mean Titer Ratios of Antibodies Against Each Dengue Serotype In Flavivirus-Immune Participants Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) immune participants at baseline are defined as those participants with ≥10 (1/dil) for at least one serotype with the parental dengue virus strain or for Japanese encephalitis (JE) virus.","populationDescription":"Geometric mean titers ratios were assessed in the Full Analysis Set with available data for each time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer ratio","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants who received 3 vaccinations of the CYD Dengue Vaccine."},{"id":"OG001","title":"Placebo Group","description":"Healthy adult participants who received 3 vaccinations of placebo vaccine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"56"}]}],"classes":[{"title":"Serotype 1; Post-inj. 1/Pre-inj. 1 (N=112,56)","categories":[{"measurements":[{"groupId":"OG000","value":"3.24","lowerLimit":"2.47","upperLimit":"4.25"},{"groupId":"OG001","value":"1.22","lowerLimit":"0.994","upperLimit":"1.49"}]}]},{"title":"Serotype 1; Post-inj. 2/Pre-inj. 1 (N=104,53)","categories":[{"measurements":[{"groupId":"OG000","value":"2.93","lowerLimit":"2.28","upperLimit":"3.77"},{"groupId":"OG001","value":"1.29","lowerLimit":"1.01","upperLimit":"1.65"}]}]},{"title":"Serotype 1; Post-inj. 3/Pre-inj. 1 (N=102,52)","categories":[{"measurements":[{"groupId":"OG000","value":"2.31","lowerLimit":"1.82","upperLimit":"2.94"},{"groupId":"OG001","value":"1.10","lowerLimit":"0.786","upperLimit":"1.55"}]}]},{"title":"Serotype 2; Post-inj. 1/Pre-inj. 1 (N=113,56)","categories":[{"measurements":[{"groupId":"OG000","value":"3.30","lowerLimit":"2.59","upperLimit":"4.20"},{"groupId":"OG001","value":"1.20","lowerLimit":"1.01","upperLimit":"1.43"}]}]},{"title":"Serotype 2; Post-inj. 2/Pre-inj. 1 (N=104,53)","categories":[{"measurements":[{"groupId":"OG000","value":"3.09","lowerLimit":"2.34","upperLimit":"4.08"},{"groupId":"OG001","value":"1.19","lowerLimit":"0.946","upperLimit":"1.50"}]}]},{"title":"Serotype 2; Post-inj. 3/Pre-inj. 1 (N=102,52)","categories":[{"measurements":[{"groupId":"OG000","value":"1.91","lowerLimit":"1.49","upperLimit":"2.45"},{"groupId":"OG001","value":"1.00","lowerLimit":"0.746","upperLimit":"1.35"}]}]},{"title":"Serotype 3; Post-inj. 1/Pre-inj. 1 (N=113,56)","categories":[{"measurements":[{"groupId":"OG000","value":"3.92","lowerLimit":"3.00","upperLimit":"5.13"},{"groupId":"OG001","value":"1.34","lowerLimit":"1.07","upperLimit":"1.69"}]}]},{"title":"Serotype 3; Post-inj. 2/Pre-inj. 1 (N=104,53)","categories":[{"measurements":[{"groupId":"OG000","value":"3.32","lowerLimit":"2.50","upperLimit":"4.41"},{"groupId":"OG001","value":"1.15","lowerLimit":"0.878","upperLimit":"1.50"}]}]},{"title":"Serotype 3; Post-inj. 3/Pre-inj. 1 (N=102,52)","categories":[{"measurements":[{"groupId":"OG000","value":"2.71","lowerLimit":"2.10","upperLimit":"3.49"},{"groupId":"OG001","value":"1.17","lowerLimit":"0.820","upperLimit":"1.67"}]}]},{"title":"Serotype 4; Post-inj. 1/Pre-inj. 1 (N=113,56)","categories":[{"measurements":[{"groupId":"OG000","value":"5.80","lowerLimit":"4.23","upperLimit":"7.96"},{"groupId":"OG001","value":"1.28","lowerLimit":"0.988","upperLimit":"1.65"}]}]},{"title":"Serotype 4; Post-inj. 2/Pre-inj. 1 (N=104,52)","categories":[{"measurements":[{"groupId":"OG000","value":"4.86","lowerLimit":"3.48","upperLimit":"5.99"},{"groupId":"OG001","value":"1.17","lowerLimit":"0.912","upperLimit":"1.50"}]}]},{"title":"Serotype 4; Post-inj. 3/Pre-inj. 1 (N=102,52)","categories":[{"measurements":[{"groupId":"OG000","value":"5.18","lowerLimit":"4.03","upperLimit":"6.66"},{"groupId":"OG001","value":"1.43","lowerLimit":"1.06","upperLimit":"1.93"}]}]}]},{"type":"SECONDARY","title":"Summary of Geometric Mean Titers of Antibodies Against Each Dengue Serotype In Flavivirus Non-immune Participants Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) non immune participants at baseline are defined as those participants with \\<10 (1/dil) for all serotypes with parental dengue virus strains and for Japanese encephalitis (JE) virus.","populationDescription":"Geometric mean titers were assessed in the Full Analysis Set with available data for each time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers (1/dilutions)","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants received 3 vaccinations of the CYD Dengue Vaccine."},{"id":"OG001","title":"Placebo Group","description":"Healthy adult participants received 3 vaccinations of placebo vaccine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}]}],"classes":[{"title":"Serotype 1; Pre-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"},{"groupId":"OG001","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"}]}]},{"title":"Serotype 1; Post-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"15.5","lowerLimit":"5.83","upperLimit":"41.3"},{"groupId":"OG001","value":"7.01","lowerLimit":"2.75","upperLimit":"17.9"}]}]},{"title":"Serotype 1; Post-injection 2 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"28.2","lowerLimit":"9.88","upperLimit":"80.4"},{"groupId":"OG001","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"}]}]},{"title":"Serotype 1; Post-injection 3 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"37.1","lowerLimit":"16.0","upperLimit":"86.5"},{"groupId":"OG001","value":"11.8","lowerLimit":"1.09","upperLimit":"126"}]}]},{"title":"Serotype 2; Pre-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"},{"groupId":"OG001","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"}]}]},{"title":"Serotype 2; Post-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"32.1","lowerLimit":"9.14","upperLimit":"112"},{"groupId":"OG001","value":"8.27","lowerLimit":"2.04","upperLimit":"33.5"}]}]},{"title":"Serotype 2; Post-injection 2 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"107","lowerLimit":"27.9","upperLimit":"410"},{"groupId":"OG001","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"}]}]},{"title":"Serotype 2; Post-injection 3 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"66.8","lowerLimit":"22.8","upperLimit":"196"},{"groupId":"OG001","value":"8.93","lowerLimit":"1.78","upperLimit":"44.7"}]}]},{"title":"Serotype 3; Pre-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"},{"groupId":"OG001","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"}]}]},{"title":"Serotype 3; Post-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"53.8","lowerLimit":"17.7","upperLimit":"163"},{"groupId":"OG001","value":"5.96","lowerLimit":"3.66","upperLimit":"9.69"}]}]},{"title":"Serotype 3; Post-injection 2 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"83.1","lowerLimit":"30.3","upperLimit":"228"},{"groupId":"OG001","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"}]}]},{"title":"Serotype 3; Post-injection 3 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"98.6","lowerLimit":"48.1","upperLimit":"202"},{"groupId":"OG001","value":"9.72","lowerLimit":"1.53","upperLimit":"61.6"}]}]},{"title":"Serotype 4; Pre-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"},{"groupId":"OG001","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"}]}]},{"title":"Serotype 4; Post-injection 1 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"81.8","lowerLimit":"25.0","upperLimit":"267"},{"groupId":"OG001","value":"5.96","lowerLimit":"3.66","upperLimit":"9.69"}]}]},{"title":"Serotype 4; Post-injection 2 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"68.4","lowerLimit":"33.3","upperLimit":"141"},{"groupId":"OG001","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"}]}]},{"title":"Serotype 4; Post-injection 3 (N=13, 5)","categories":[{"measurements":[{"groupId":"OG000","value":"111","lowerLimit":"79.9","upperLimit":"155"},{"groupId":"OG001","value":"7.29","lowerLimit":"2.56","upperLimit":"20.8"}]}]}]},{"type":"SECONDARY","title":"Summary of Geometric Mean Titer Ratios of Antibodies Against Each Dengue Serotype In Flavivirus Non-immune Participants Before and After Each Vaccination With Either Tetravalent Dengue Vaccine or a Placebo","description":"Dengue neutralizing antibody levels were measured by dengue plaque reduction neutralization test (PRNT). Flavivirus (FV) immune participants at baseline are defined as those participants with ≥10 (1/dil) for at least one serotype with the parental dengue virus strain or for Japanese encephalitis (JE) virus.","populationDescription":"Geometric mean titers ratios were assessed in the Full Analysis Set with available data for each time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer ratio","timeFrame":"Pre-injection 1 and 28 days post each injection (up to 13 months post-injection 1)","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants who received 3 vaccinations of the CYD Dengue Vaccine."},{"id":"OG001","title":"Placebo Group","description":"Healthy adult participants who received 3 vaccinations of placebo vaccine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}]}],"classes":[{"title":"Serotype 1; Post-inj. 1/Pre-inj. 1 (N=13,5)","categories":[{"measurements":[{"groupId":"OG000","value":"3.10","lowerLimit":"1.17","upperLimit":"8.25"},{"groupId":"OG001","value":"1.40","lowerLimit":"0.549","upperLimit":"3.57"}]}]},{"title":"Serotype 1; Post-inj. 2/Pre-inj. 1 (N=13,5)","categories":[{"measurements":[{"groupId":"OG000","value":"5.64","lowerLimit":"1.98","upperLimit":"16.1"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.00","upperLimit":"1.00"}]}]},{"title":"Serotype 1; Post-inj. 3/Pre-inj. 1 (N=13,5)","categories":[{"measurements":[{"groupId":"OG000","value":"7.43","lowerLimit":"3.19","upperLimit":"17.3"},{"groupId":"OG001","value":"2.35","lowerLimit":"0.219","upperLimit":"25.3"}]}]},{"title":"Serotype 2; Post-inj. 1/Pre-inj. 1 (N=13,5)","categories":[{"measurements":[{"groupId":"OG000","value":"6.41","lowerLimit":"1.83","upperLimit":"22.5"},{"groupId":"OG001","value":"1.65","lowerLimit":"0.409","upperLimit":"6.70"}]}]},{"title":"Serotype 2; Post-inj. 2/Pre-inj. 1 (N=13,5)","categories":[{"measurements":[{"groupId":"OG000","value":"21.4","lowerLimit":"5.59","upperLimit":"81.9"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.00","upperLimit":"1.00"}]}]},{"title":"Serotype 2; Post-inj. 3/Pre-inj. 1 (N=13,5)","categories":[{"measurements":[{"groupId":"OG000","value":"13.4","lowerLimit":"4.56","upperLimit":"39.1"},{"groupId":"OG001","value":"1.79","lowerLimit":"0.357","upperLimit":"8.95"}]}]},{"title":"Serotype 3; Post-inj. 1/Pre-inj. 1 (N=13,5)","categories":[{"measurements":[{"groupId":"OG000","value":"10.8","lowerLimit":"3.55","upperLimit":"32.6"},{"groupId":"OG001","value":"1.58","lowerLimit":"0.441","upperLimit":"5.69"}]}]},{"title":"Serotype 3; Post-inj. 2/Pre-inj. 1 (N=13,5)","categories":[{"measurements":[{"groupId":"OG000","value":"16.6","lowerLimit":"6.06","upperLimit":"45.5"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.00","upperLimit":"1.00"}]}]},{"title":"Serotype 3; Post-inj. 3/Pre-inj. 1 (N=13,5)","categories":[{"measurements":[{"groupId":"OG000","value":"19.7","lowerLimit":"9.63","upperLimit":"40.4"},{"groupId":"OG001","value":"1.94","lowerLimit":"0.307","upperLimit":"12.3"}]}]},{"title":"Serotype 4; Post-inj. 1/Pre-inj. 1 (N=13,5)","categories":[{"measurements":[{"groupId":"OG000","value":"16.4","lowerLimit":"5.01","upperLimit":"53.4"},{"groupId":"OG001","value":"1.19","lowerLimit":"0.733","upperLimit":"1.94"}]}]},{"title":"Serotype 4; Post-inj. 2/Pre-inj. 1 (N=13,5)","categories":[{"measurements":[{"groupId":"OG000","value":"13.7","lowerLimit":"6.66","upperLimit":"28.1"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.00","upperLimit":"1.00"}]}]},{"title":"Serotype 4; Post-inj. 3/Pre-inj. 1 (N=13,5)","categories":[{"measurements":[{"groupId":"OG000","value":"22.2","lowerLimit":"16.0","upperLimit":"31.0"},{"groupId":"OG001","value":"1.46","lowerLimit":"0.511","upperLimit":"4.16"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5.00","timeFrame":"Adverse event data were collected from Day 0 up to 1 year post injection 1.","eventGroups":[{"id":"EG000","title":"CYD Dengue Vaccine Group","description":"Healthy adult participants received 3 vaccinations of the CYD Dengue Vaccine.","seriousNumAffected":1,"seriousNumAtRisk":127,"otherNumAffected":14,"otherNumAtRisk":127},{"id":"EG001","title":"Placebo Group","description":"Healthy adult participants received 3 vaccinations of placebo vaccine.","seriousNumAffected":1,"seriousNumAtRisk":61,"otherNumAffected":3,"otherNumAtRisk":61}],"seriousEvents":[{"term":"Anaemia megaloblastic","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":127},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":127},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":127},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61}]}],"otherEvents":[{"term":"Injection site Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":127},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":61}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":126},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":126},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":61}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":126},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":61}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":126},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":61}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":126},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":61}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications."},"pointOfContact":{"title":"Medical Director","organization":"Sanofi Pasteur Inc.","email":"RegistryContactUs@sanofipasteur.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D003715","term":"Dengue"},{"id":"D019595","term":"Severe Dengue"}],"ancestors":[{"id":"D000096724","term":"Mosquito-Borne Diseases"},{"id":"D000079426","term":"Vector Borne Diseases"},{"id":"D007239","term":"Infections"},{"id":"D001102","term":"Arbovirus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D018177","term":"Flavivirus Infections"},{"id":"D018178","term":"Flaviviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D006482","term":"Hemorrhagic Fevers, Viral"}]},"interventionBrowseModule":{"meshes":[{"id":"D012996","term":"Solutions"}],"ancestors":[{"id":"D004364","term":"Pharmaceutical Preparations"}]}},"hasResults":true}